Have you been paying attention to shares of ICU Medical (ICUI) ? Shares have been on the move with the stock up 27.6% over the past month. The stock hit a new 52-week high of $160 in the previous session. ICU Medical has gained 59.2% since the start of the year compared to the 11.1% move for the Zacks Medical sector and the 10.2% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earn ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are und ...

ICU Medical (ICUI) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.88 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 59.18%. A quarter ago, it was expected that this medical device maker would post earnings of $0.84 per share when it actually produced earnings of $0.96, delivering a surprise of 14.29%. Over the last four quarters, th ...

Core Points - ICU Medical, Inc. will release its second quarter 2024 earnings results on August 7, 2024, at approximately 4:00 p.m. ET [2] - A conference call to discuss the results will take place on the same day at 4:30 p.m. ET, accessible via phone and webcast [2] - ICU Medical is a leader in infusion systems and critical care products, focusing on quality and innovation for clinical customers worldwide [3]

ICU Medical (ICUI) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $1.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this medical device maker would post earnings of $1.18 per share when it actually produced earnings of $1.57, delivering a surprise of 33.05%.Over the last four quarters, the ...

ICU Medical, Inc Q1 2024 Conference Call Presentation May 7, 2024 > Any statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results. > These forward-looking statements, including statements about continuing health crises, pandemics and epidemics, such as th ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 (Former name, former address and former fiscal year, if changed since last report) For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exact name of registrant as spe ...

[Financial Highlights (Q1 2024)](index=1&type=section&id=First%20Quarter%202024%20Results) ICU Medical reported first-quarter 2024 revenue of $566.7 million, a slight decrease from $568.6 million in the prior year. The company experienced a significant increase in GAAP net loss to $(39.5) million, compared to a $(9.8) million loss in Q1 2023. Both Adjusted EBITDA and Adjusted Diluted EPS saw substantial declines, falling to $78.8 million and $0.96, respectively Financial Highlights Summary | Financial Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $566.7 million | $568.6 million | -0.3% | | **GAAP Gross Profit** | $185.2 million | $192.0 million | -3.5% | | **GAAP Gross Margin** | 33% | 34% | -1 ppt | | **GAAP Net Loss** | $(39.5) million | $(9.8) million | +303% | | **GAAP Diluted EPS** | $(1.63) | $(0.41) | +298% | | **Adjusted EBITDA** | $78.8 million | $102.0 million | -22.7% | | **Adjusted Diluted EPS** | $0.96 | $1.74 | -44.8% | - The company's CEO, Vivek Jain, stated that the first-quarter results were generally in line with expectations[5](index=5&type=chunk) [Revenue by Product Line](index=1&type=section&id=Revenues%20by%20product%20line) For the first quarter of 2024, the Consumables segment was the only product line to show growth, increasing by $8.0 million year-over-year. Both Infusion Systems and Vital Care segments experienced revenue declines of $4.4 million and $5.5 million respectively, contributing to the slight overall decrease in total revenue Revenue by Product Line Summary | Product Line | Q1 2024 Revenue (in millions) | Q1 2023 Revenue (in millions) | Change (in millions) | | :--- | :--- | :--- | :--- | | Consumables | $244.1 | $236.1 | $8.0 | | Infusion Systems | $157.3 | $161.7 | $(4.4) | | Vital Care | $165.3 | $170.8 | $(5.5) | | **Total** | **$566.7** | **$568.6** | **$(1.9)** | - Pfizer contract manufacturing revenue, which is included in the Vital Care segment, increased to **$14.1 million** in Q1 2024 from **$12.7 million** in Q1 2023[5](index=5&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) The company's financial statements detail its financial position and performance. As of March 31, 2024, total assets were $4.29 billion. The statement of operations shows a net loss of $(39.5) million for the quarter, a significant increase from the $(9.8) million loss in the prior-year period. The company generated $45.8 million in cash from operations [Condensed Consolidated Balance Sheets](index=4&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) Condensed Consolidated Balance Sheets Summary | Balance Sheet Item (in thousands) | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $251,423 | $254,222 | | Inventories | $693,006 | $709,360 | | **Total Assets** | **$4,288,398** | **$4,378,439** | | Current portion of long-term debt | $51,000 | $51,000 | | Long-term debt | $1,566,298 | $1,577,770 | | **Total Liabilities** | **$2,220,568** | **$2,255,029** | | **Total Stockholders' Equity** | **$2,067,830** | **$2,123,410** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Condensed Consolidated Statements of Operations Summary | P&L Item (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Total Revenues | $566,655 | $568,649 | | Gross Profit | $185,244 | $192,041 | | (Loss) Income from Operations | $(10,655) | $9,395 | | **Net Loss** | **$(39,471)** | **$(9,812)** | | **Diluted Net Loss Per Share** | **$(1.63)** | **$(0.41)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Condensed Consolidated Statements of Cash Flows Summary | Cash Flow Item (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $45,791 | $41,245 | | Net cash used in investing activities | $(17,862) | $(15,183) | | Net cash used in financing activities | $(26,845) | $(15,837) | | **Net (Decrease) Increase in Cash** | **$(2,799)** | **$12,163** | [Non-GAAP Financial Measures](index=8&type=section&id=Use%20of%20Non-GAAP%20Financial%20Information) The company utilizes non-GAAP measures like Adjusted EBITDA, Adjusted Diluted EPS, and Free Cash Flow to supplement its GAAP results. Management believes these metrics offer a clearer view of operational performance by excluding special items that are variable or unusual, such as stock compensation, amortization, restructuring costs, and certain quality-related charges, thereby facilitating more meaningful period-over-period comparisons - The company uses non-GAAP financial measures to supplement GAAP results, believing they provide useful information for management and investors to assess business performance and facilitate comparisons between periods[17](index=17&type=chunk) - Special items excluded from non-GAAP calculations include stock compensation, intangible asset amortization, restructuring and integration costs, changes in fair value of contingent earn-outs, and quality system remediation charges[19](index=19&type=chunk)[20](index=20&type=chunk)[21](index=21&type=chunk) [Reconciliation of GAAP to Non-GAAP Financial Measures](index=10&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) Reconciliation to Adjusted EBITDA | Reconciliation to Adjusted EBITDA (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | GAAP net loss | $(39,471) | $(9,812) | | Total non-GAAP adjustments | $118,278 | $111,793 | | **Adjusted EBITDA** | **$78,807** | **$101,981** | Reconciliation to Adjusted Diluted EPS | Reconciliation to Adjusted Diluted EPS | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Reported GAAP diluted (loss) per share | $(1.63) | $(0.41) | | Adjustments (Amortization, Stock Comp, etc.) | $2.59 | $2.15 | | **Adjusted (Non-GAAP) diluted earnings per share** | **$0.96** | **$1.74** | [Reconciliation to Free Cash Flow](index=14&type=section&id=Reconciliation%20of%20Net%20Cash%20Provided%20by%20Operating%20Activities%20to%20Free%20Cash%20Flow) Reconciliation to Free Cash Flow | Free Cash Flow Calculation (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $45,791 | $41,245 | | Purchase of property, plant and equipment | $(15,915) | $(14,205) | | Proceeds from sale of assets | $507 | $54 | | **Free cash flow** | **$30,383** | **$27,094** | [Fiscal Year 2024 Outlook](index=15&type=section&id=Fiscal%20Year%202024%20Outlook) ICU Medical provided its full-year 2024 guidance, projecting an Adjusted EBITDA between $330 million and $370 million, and Adjusted Diluted EPS in the range of $4.40 to $5.10. This outlook reflects updates from the guidance previously issued on February 27, 2024, and includes significant non-GAAP adjustments from the projected GAAP net loss Fiscal Year 2024 Guidance Summary | FY 2024 Guidance | Low End | High End | | :--- | :--- | :--- | | Adjusted EBITDA (in millions) | $330 | $370 | | Adjusted Diluted EPS | $4.40 | $5.10 | - The provided guidance reflects updates from the full-year outlook that was published on February 27, 2024[40](index=40&type=chunk) [Other Information](index=1&type=section&id=Other%20Information) This section provides details for the investor conference call held on May 7, 2024, to discuss the quarterly results. It also includes the standard forward-looking statement disclaimer, which outlines potential risks and uncertainties—such as demand fluctuations, competition, and integration challenges—that could cause actual results to differ from management's expectations - The company hosted a conference call and webcast on May 7, 2024, to discuss its first-quarter financial results[7](index=7&type=chunk) - The report contains forward-looking statements subject to risks and uncertainties, including decreased product demand, competition, inflation, and challenges with the integration of the Smiths Medical business[9](index=9&type=chunk)[10](index=10&type=chunk)

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. ...

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. ...